These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1662891)

  • 1. In vitro activity of temafloxacin against pathogens causing sexually transmitted diseases.
    Segreti J
    Am J Med; 1991 Dec; 91(6A):24S-26S. PubMed ID: 1662891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.
    Hoban D; DeGagne P; Witwicki E
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):83S-86S. PubMed ID: 2507222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
    Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB
    Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.
    Tjiam KH; Wagenvoort JH; van Klingeren B; Piot P; Stolz E; Michel MF
    Eur J Clin Microbiol; 1986 Oct; 5(5):498-501. PubMed ID: 3096726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activity of sparfloxacin against genital pathogens.
    Perea EJ; Aznar J; Garcia-Iglesias MC; Pascual A
    J Antimicrob Chemother; 1996 May; 37 Suppl A():19-25. PubMed ID: 8737122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1726-7. PubMed ID: 8215294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of fluoroquinolones in sexually transmitted diseases.
    Tartaglione TA; Hooton TM
    Pharmacotherapy; 1993; 13(3):189-201. PubMed ID: 8321733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.
    Furneri PM; Bisignano G; Cerniglia G; Nicoletti G; Cesana M; Tempera G
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2651-4. PubMed ID: 7872762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.
    Segreti J; Hirsch DJ; Harris AA; Kapell KS; Orbach H; Kessler HA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):971-3. PubMed ID: 2118330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolones for the treatment of nongonococcal urethritis/cervicitis.
    Segreti J
    Am J Med; 1991 Dec; 91(6A):150S-152S. PubMed ID: 1662887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis in patients with non-gonococcal urethritis.
    Kilic D; Basar MM; Kaygusuz S; Yilmaz E; Basar H; Batislam E
    Jpn J Infect Dis; 2004 Feb; 57(1):17-20. PubMed ID: 14985631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum.
    Dobson RA; O'Connor JR; Poulin SA; Kundsin RB; Smith TF; Came PE
    Antimicrob Agents Chemother; 1980 Nov; 18(5):738-40. PubMed ID: 6778385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):12S-14S. PubMed ID: 1662881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of azithromycin against Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in comparison with erythromycin, roxithromycin and minocycline.
    Rumpianesi F; Morandotti G; Sperning R; Satta G; Cevenini R
    J Chemother; 1993 Jun; 5(3):155-8. PubMed ID: 8396626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical effect of NY-198 (lomefloxacin) for sexually transmitted disease--bacteriological effect of U. urealyticum].
    Kawamura N; Nishizawa K; Kawashima T; Koinuma A; Ohhara K
    Kansenshogaku Zasshi; 1990 Jan; 64(1):1-11. PubMed ID: 2335746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
    Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of lomefloxacin, tetracycline, penicillin, spectinomycin, and ceftriaxone against Neisseria gonorrhoeae and Chlamydia trachomatis.
    Talbot H; Romanowski B
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2049-51. PubMed ID: 2533473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
    Waites KB; Cassell GH; Canupp KC; Fernandes PB
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1500-2. PubMed ID: 2973283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.